Skip to Content
Home > Care & Treatment > Payson Center for Cancer Care > Clinical Trials > Clinical Trials Search Results
Patients with advanced non-small cell lung cancer whose tumor’s have high levels of COX-2 may be eligible for this study. The purpose of the study is to see if adding celecoxib versus placebo to standard chemotherapy has any benefit.
Comparing bevacizumab and erlotinib versus erlotinib alone to determine if the amount of time before tumor growth is seen is longer with the two drug combination.
Must be getting radiation and chemotherapy treatment at the same time. There are 3 groups. One group will not get the honey. One group will get the honey in liquid form to be taken four 4 times/day. One group will get the honey in a lozenge form 4 times/day. Groups will be compared to see which group has less throat pain.
Patients with advanced stage IIIB/IV non-small cell lung cancer may be eligible for this study. Patients will be randomized to receive either Sunitinib or placebo after standard chemotherapy to see if Sunitinib helps their tumor shrink or stop growing.
© 2015 Concord Hospital